MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bönisch, D.
Right arrow Articles by Schrör, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bönisch, D.
Right arrow Articles by Schrör, K.

Vol. 54, Issue 2, 241-248, August 1998

Antimitogenic Effects of Trapidil In Coronary Artery Smooth Muscle Cells by Direct Activation of Protein Kinase A

Detlef Bönisch, Artur-Aron Weber, Michael Wittpoth, Michael Osinski, and Karsten Schrör

Institut für Pharmakologie, Heinrich-Heine-Universität, Düsseldorf, Germany

The triazolopyrimidine trapidil has been found in controlled clinical trials to prevent restenosis after vascular injury. Although trapidil is widely regarded as a platelet-derived growth factor receptor (PDGF) antagonist, its precise mode of action is still unknown. This study was designed to investigate the inhibition of mitogenesis by trapidil in cultured bovine coronary artery smooth muscle cells (SMC) and to identify major signal transduction pathways involved. Trapidil inhibited PDGF-BB-induced mitogenesis in SMC in a concentration-dependent manner. Comparable inhibitory effects were obtained after stimulation of smooth muscle cells by phorbol ester, which suggests that the action of trapidil was not restricted to PDGF receptor-mediated mechanisms. Trapidil also inhibited PDGF- and phorbol ester-induced mitogen-activated protein kinase as well as Raf-1 kinase activity. As a possible target of trapidil, stimulation of cellular protein kinase A (PKA) activity was detected. Trapidil also induced the phosphorylation of vasodilator-stimulated phosphoprotein in SMC. Antimitogenic effects of trapidil were completely abolished by PKA inhibitors. Neither a direct stimulation of cAMP formation nor a phosphodiesterase inhibition was observed at antimitogenic concentrations of trapidil. However, trapidil directly activated purified PKA holoenzyme in a cAMP-independent manner. In conclusion, trapidil exerts its antimitogenic effects on SMC by direct activation of PKA. Thus, PKA-mediated inhibition of the Raf-1/MAP kinase pathway may be involved in the antimitogenic actions of the compound.

Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 EndocrinologyHome page
M. B. Lowry, S. Lotinun, A. A. Leontovich, M. Zhang, A. Maran, K. L. Shogren, B. K. Palama, K. Marley, U. T. Iwaniec, and R. T. Turner
Osteitis Fibrosa Is Mediated by Platelet-Derived Growth Factor-A Via a Phosphoinositide 3-Kinase-Dependent Signaling Pathway in a Rat Model for Chronic Hyperparathyroidism
Endocrinology, November 1, 2008; 149(11): 5735 - 5746.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
O. J Sichelschmidt, C. Hahnefeld, T. Hohlfeld, F. W Herberg, and K. Schror
Trapidil protects ischemic hearts from reperfusion injury by stimulating PKAII activity
Cardiovasc Res, June 1, 2003; 58(3): 602 - 610.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Lotinun, J. D. Sibonga, and R. T. Turner
Triazolopyrimidine (Trapidil), a Platelet-Derived Growth Factor Antagonist, Inhibits Parathyroid Bone Disease in an Animal Model for Chronic Hyperparathyroidism
Endocrinology, May 1, 2003; 144(5): 2000 - 2007.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. Onimaru, Y. Yonemitsu, M. Tanii, K. Nakagawa, I. Masaki, S. Okano, H. Ishibashi, K. Shirasuna, M. Hasegawa, and K. Sueishi
Fibroblast Growth Factor-2 Gene Transfer Can Stimulate Hepatocyte Growth Factor Expression Irrespective of Hypoxia-Mediated Downregulation in Ischemic Limbs
Circ. Res., November 15, 2002; 91(10): 923 - 930.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
R Jaster, G Sparmann, J Emmrich, and S Liebe
Extracellular signal regulated kinases are key mediators of mitogenic signals in rat pancreatic stellate cells
Gut, October 1, 2002; 51(4): 579 - 584.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P.W. Serruys, D.P. Foley, M. Pieper, J.A. Kleijne, and P.J. de Feyter on behalf of the TRAPIST investigators
The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound
Eur. Heart J., October 2, 2001; 22(20): 1938 - 1947.
[Abstract] [PDF]

Home page
 Mol. Pharmacol.Home page
M. T. Osinski, B. H. Rauch, and K. Schrör
Antimitogenic Actions of Organic Nitrates Are Potentiated by Sildenafil and Mediated Via Activation of Protein Kinase A
Mol. Pharmacol., April 16, 2001; 59(5): 1044 - 1050.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
J. F. Kuemmerle and K. S. Murthy
Coupling of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase to Gi2 in Human Intestinal Smooth Muscle. Gbeta gamma -DEPENDENT MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATION AND GROWTH
J. Biol. Chem., March 2, 2001; 276(10): 7187 - 7194.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics